Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: University of Aarhus
• Treatments: Amiloride; Arginine Vasopressin; Calcitonin; Calcitonin Gene-Related Peptide; Hydrochlorothiazide; Indomethacin; Katacalcin; Salmon calcitonin; Sildenafil Citrate

Criteria

Inclusion Criteria:

• Known diagnosis of Congenital Nephrogenic Diabetes Insipidus (CNDI)

• Age 5 to 25 years

• Normal kidney function

• Post-void residual urine < 200 ml (determined by bladder ultrasound)

Exclusion Criteria:

• Impaired kidney function

• Known urinary retention or bladder dysfunction

• High blood pressure

• Other significant chronic medical disease (e.g., heart failure, liver disease, etc.)

• Allergy to study drugs